Berbel J.R. Sluijter

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression

Inge S. van Houdt, Berbel J.R. Sluijter, Laura M Moesbergen et al. · International Journal of Cancer · 2008 · 138 citations · Full text

Life Sciences, Immunology, Oncology +17

Intradermal CpG-B Activates Both Plasmacytoid and Myeloid Dendritic Cells in the Sentinel Lymph Node of Melanoma Patients

Barbara G. Molenkamp, Paul A.M. van Leeuwen, Sybren Meijer et al. · Clinical Cancer Research · 2007 · 126 citations · Full text

Life Sciences, Immunology, Oncology +17

Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients

Barbara G. Molenkamp, Berbel J.R. Sluijter, Paul A.M. van Leeuwen et al. · Clinical Cancer Research · 2008 · 123 citations

Life Sciences, Immunology, Oncology +17

Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation

Rieneke van de Ven, Mari F.C.M. van den Hout, Jelle J. Lindenberg et al. · Blood · 2011 · 92 citations · Full text

Life Sciences, Cell Biology, Immunology +16

Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials

Bas D. Koster, Mari F.C.M. van den Hout, Berbel J.R. Sluijter et al. · Clinical Cancer Research · 2017 · 64 citations · Full text

Medicine, Immunology, Oncology +17